Bioprogress is a stock I have been in and out of quite a few times since it floated in May but not much mention here on the Investors' Room. Does anyone else follow this stock. I see it is up 1.5p today and a few good buyers seem to have appeared.

Still looking good


Interview with Richard Trevillion

Richard Trevillion has conducted a 10-minute interview with CEOcast and has been approved by Dan for release.

http://www.ceocast.com/company.cfm?cid=19351



For the record, here is a transcript of this Ceocast interview 22 November 2005 (I have edited it for grammar etc to make it read better):


Michael: Good-day, this is Michael Wax with Ceocast. Im here today with Richard Travillion, Richard is Chief Executive Officer of BioProgress plc. A company that trades on the NASDAQ, under the symbol BPRG, one that is a European based company. Thanks for joining Ceocast, Richard.

Richard: My pleasure.

Michael: Perhaps you could begin with an overview of the company, and then what I thought we would do is get into the business in greater detail and talk about some of your trading results.

Richard: OK, will do. As an overview, BioProgress was established to exploit the uses of non-gelatin film for a variety of industrial uses. Over time, the company has focused on the exploitation of the non-gelatin film, both in ingestible form and non-ingestible form. And in particular, in using film as a means of encapsulating a variety of substances and over time focusing on the health-care market in particular the pharmaceutical market and the medical-device market. Currently we have a range of grounded solutions across those two market areas. In the pharmaceutical market we provide alternatives to gelatin, sugar-coating, and other industry normal means of encapsulating pharmaceutical orally delivered products. Replacing the traditional powder-coating methods and encapsulation, providing alternative to tablet-coating, [and] providing an alternative to liquid encapsulation. And we also have the ability to encapsulate in the film itself on a film strip a variety of active substances as well as bits of mineral substances.

On the non-ingestible side, as I described, the medical-device side, we have a range of technologies used for encapsulating a variety of medical-waste. And we currently have a number of partnerships, both across those industry areas, going from the medical-device to the pharma. On medical-devices we have a partnership with a division of Bristol-Myers-Squib called Convatec. And we are working with them using our non-ingestible technology in the field of ostomy.

We also have a partnership with FMC BioPolymer, for our encapsulation of powder, pharmaceutical powder encapsulation. And we have a number of relationships with our film-strip technology.

Michael: You recently developed, or delivered your first NRobe machine for powder encapsulation. How big a market opportunity is this?

Richard: The market for oral-ingested pharmaceutical products is vast, and there are various definitions of that market, ranging upwards of $500 billion. The powder element of that is difficult to quantify, because most pharmaceutical products, the actives can be constituted either in a powder, liquid or hard-tablet fashion. So its particularly complicated to provide the market in such a way. But what I think it is possible to say is that it is a meaningful portion of that market size. Clearly most ingestible pharmaceutical products have presentations in the form of powder, so we are certainly looking at a very large and growing market segment.

Michael: As you look at the Tabwrap machine, whats the opportunity here, and how far off from market do you think you are?

Richard: The Tabwrap machine is the brand we use to.. for.. is actually the replacing the traditional forms of hard-tablet coating. NRobe, as I mentioned before, covers the powder-coating. Once again, breaking the market down into tablets verses powder, verses liquid, verses other forms, is fraught with difficulties. But we showcased our prototype Tabwrap machine at a recent global event housed in Madrid a few weeks ago. The reception we got from that was extremely encouraging, and we are in the process of, like the rest of our technologies, in aggressively commercializing this as an alternative to current methods.

Michael: Given the opportunities with partners, what types of partners have you focused on?

Richard: Traditionally the company has attracted a number of very large partners. Addressing that question looking at both our areas, that being pharmaceuticals i.e. the ingestible and the medical-devices. Both industries, although dominated by some very large players, are still fairly fragmented. And also both industries are supported by other industries, for example the contract manufacturing industry, who also represent potential partners to the business. So the answer, I think to the question is we are in discussions with a number of organizations across the size[entire?] spectrum. Both principle players within those particular segments but also players that are supportive or support industries of those players.

Michael: What kind of catalysts will there be, perhaps for sales growth?

Richard: Well, in terms of the sales, we have currently two revenue streams within the business. Our core historic platform technologies, the model is one of licensing and royalties, whereby we license out the rights to use the technologies thereby not encumbering ourselves with a very expensive infrastructure. And thats relevant to all the technologies I have previously described bar the in-the-mouth, or using the film as a delivery technology in its own right.

Focusing on that for a moment, which in fact was brought us into the business through an acquisition last year. The in-the-mouth instantly dissolving film, we have a division that operates out of Florida in the US, which as you very rightly said, the first part of the year had very sluggish sales. Youll no doubt have noticed from the web site and the various announcements we have made to the market, that the company has gone through a fairly extensive restructuring exercise of the course of the past 6 to 9 months. And that has been a very lengthy but whats becoming a very successful exercise, and we are expecting there to be a very distinct improvement following that restructuring.

Michael: As you now look at the opportunities going forward, where do acquisitions or in-licensing of products fit in?

Richard: As a business we will always look at opportunities that fits within both our core constancies and also fit within both our.. that are allied to our business model. In terms of in-licensing, I think once again, the same applies. The industry in which we operate is one that is in constant change, constant evolution, and constant development, and opportunities arise on a very regular basis. And I think any company of our size and our stage in the market, will be reviewing those opportunities as they add value and create shareholder value through the synergies with the core technologies of the business over time.

Michael: What should investors now look for in the coming quarters in the terms of key developments?

Richard: The key developments, Ive hinted at one, in that, as I mentioned before, weve undergone a very extensive restructuring that was required by the company significantly underperforming and having suffered some major issues in the past. And Ive already mentioned in this interview and in previous correspondence with the market, that were expecting to elaborate on the results of that restructuring at the backend of this year.

Michael; [Wraps up].

Baza

This is getting quite exciting

Now 53/54

Yes very exciting indeed!

really. really exciting!

lol

The link below is worth a look for anyone with an interest in Bio,

http://office.innodigm.co.uk/bprg/

More of the old guard on their way!

BioProgress PLC
28 November 2005

BioProgress PLC
28 November 2005


BioProgress plc
('BioProgress' or the 'Company')

Resignation of director

BioProgress announces that Larry Shattles, a US based Executive Director, has
resigned from the board of directors with immediate effect.

For further details please contact:

BioProgress plc 01354 655674
Richard Trevillion, Chief Executive Officer
www.bioprogress.com

Dan Farrow, Finance Director

Northbank Communications 020 78868150
Katja Stout/Emma Palmer

Forward-Looking Information

The Ordinary Shares of BioProgress plc are registered under the US Securities
and Exchange Act of 1934. To the extent that this announcement contains certain
'forward-looking statements' within the meaning of the Private Securities
Litigation Reform Act of 1995, this paragraph applies. These statements are
based on management's current expectations and are subject to uncertainty and
changes in circumstances. Actual results may vary materially from the
expectations contained in the forward-looking statements. The forward-looking
statements in this release include statements addressing future financial and
operating results and the timing and benefits of the reorganisation. Detailed
information about factors pertinent to the business of the company that could
cause actual results to differ is set forth in the Company's filings with the
Securities and Exchange Commission. The Company is under no obligation to (and
expressly disclaim any such obligation to) update or alter its forward-looking
statements whether as a result of new information, future events or otherwise.
This announcement is for information only and does not constitute an offer or
invitation to acquire or dispose of any securities or investment advice. The
distribution of the announcement and/or issue of securities in certain
jurisdictions may be restricted by law. Persons into whose possession this
announcement comes are required to inform themselves about and to observe such
restrictions.




This information is provided by RNS
The company news service from the London Stock Exchange

Not so exciting now...

Adie - I disagree - the RNS's of the last couple of days are exactly what is needed to kick start this company through the next phase.

The old guy would appear to have been "sacked" - perhaps he had outlived his usefulness or just did not agree with the new direction abd strategy of the company - who knows - but the new guy - even though only a NED brings in exactly the right sort of focus that is required right now - and probably a whole new network of contacts.

I see this only as good news and another piece in the jigsaw.

Looks good to me. And if the SP drops back to 49 - I will buy more (and remember I am an SEO shareholder too)

It's off again!! Any news?????

- pickud up comment - and it is only conjecture - that maybe SEO and BPRG have settled out of court - which would be good for both cos I think.

Other than that - BPRG is on an uptrend anyway and they are expecting a positive RNS before Xmas on the state of the company

The start of what is expected to be an interesting week for Bioprogress Plc.

Yep - speculation is rife that there will be an update this week of some sort

What's spooked the BPRG sp??

Have a look at this especially the videos linked to enrobe.

Investor page (Unofficial)

Not sure - but it meant I bought some more at 49

Heard a rumor that they are to release RNS in the morning, late buys today would confirm this.

Hello the MASTER
I jumped on board this afternoon @50.25,
So am hoping you are right.
Good luck to all holders

Should pick up now SEO in trouble today

Nkirk,

I would be grateful for a little more explanation about SEOs problems.

The only problems I see SEO as having, is the dissatisfaction of credulous rampers and de-rampers.

I doubt that BPRG has pleasure from that as it has had its fair share of the same treatment and owes much of its lower price to being shorted in the past.